Analogous studies in GC, CRC and lower-grade glioma (LGG) showed the overexpression of PD-L1 in patients with high m7G level 105,145,146, and the other immune checkpoint of tumor cells, CD276 showed same outcomes 147. This evidence concerns the gene CD274 and neoplasm.